drugset / Trial / NCT07145268
Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-09-01
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Zinc Sulfate | Unknown | 220 mg | Oral |
| Comparator | Entecavir | Small molecule | 0.5 mg | Oral |